// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Titin Truncating Variants Predict Life-threatening Arrhythmias in Patients With Dilated Cardiomyopathy

Ben Corden - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Coronary Reperfusion Ameliorates the Deleterious Effect of Mechanical Unloading on Infarct Size and Interstitial Fibrosis After Acute Myocardial Infarction

Sean O Bello - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Soluble Endoglin is an Independent Predictor of Blood Pressure Response to Hemodynamic Stress in Young Adults

Ashley Verburg - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

The Effects Of Prolonged Anacetrapib Therapy On First And Subsequent Occlusive Vascular Events

Emily Sammons - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Atorvastatin

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Louise Bowman - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Atorvastatin

Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Marc P Bonaca - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Evolocumab

Clinical Benefit of Evolocumab in Patients With a History of MI: An Analysis From FOURIER

Marc S Sabatine - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Evolocumab

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Sheng-chia Chung - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Kenneth W Mahaffey - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Canagliflozin

Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial

Robert J Mentz - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Exenatide

Serum Metabolomic Profiles Predict Coronary Heart Disease in the General Population - The Biomarcare Consortium

Tanja Zeller - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Costs Impact Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Andre Lamy - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

rivaroxaban

Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Jonas Oldgren - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Clopidogrel bisulfate

Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results From the REDUCE LAP-HF I Randomized Controlled Trial

Sanjiv J Shah - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

EF-40

Platelets Shift Towards a Procoagulant and Proinflammatory Phenotype at the Expense of Aggregation During Trauma Hemorrhage: a Potential Role of Extracellular Histones

Paul Vulliamy - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Galectin-3 Discriminates a Subset of Macrophages With a Pro-Fibrotic Role in Atherosclerosis

Karina Di Gregoli - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Angiology

N/A

N/A

Reducing Expression of Insulin Like Growth Factor-1 Receptors in Endothelial Cells Leads to Favourable Changes in White Adipose Tissue in the Response to Nutritional Obesity

Natalie Haywood - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Tamoxifen

Aneurysmal Dilatation of the Main Pulmonary Artery in Patients With Isolated Pulmonary Stenosis: An Intrinsic Arteriopathy or a Flow-Related Sequela?

Bram Ruijsink - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Coronary Pressure and Flow Pre and Post TAVI: Analysis of Patients With Severe Aortic Stenosis and Coronary Artery Disease: Implications for Clinical Assessment of Functional Coronary Significance

Yousif Ahmad - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Do GWTG and ADHERE Scores Predict Outcomes in Ambulatory Management of Acute Decompensated Heart Failure?

Cheuk Lee - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

furosemide GR

Copyright © 2026. QuantiNova All rights reserved